Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 5Hematologic Diseases 5Lymphoma 2Leukemia, B-Cell 2Recurrence 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Chromosome 17 deletion 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 14Gemcitabine 12Bortezomib 12Lenalidomide 11Cisplatin 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7daratumumab 6selinexor 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Injections 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × pirtobrutinib × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡